On December 5, 2020 Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, reported that new data from the Phase 2 Zella 201 study evaluating the investigational agent alvocidib, a potent CDK9 inhibitor, in patients with MCL-1 dependent acute myeloid leukemia (AML) (Press release, Sumitomo Dainippon Pharma, DEC 5, 2020, View Source [SID1234572269]). These results were presented at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, being held virtually December 5-8, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Preliminary findings from the open-label, randomized, multicenter study indicated that alvocidib was well tolerated with a manageable safety profile in combination with cytarabine and mitoxantrone in an exploratory arm of patients with newly diagnosed, high-risk MCL-1 dependent AML. Alvocidib in combination showed preliminary signs of clinical activity in the study, with 62% (n=8 of 13) of evaluable patients achieving complete remission/complete remission with incomplete count recovery. Of the patients that responded, 75% (n=6 of 8) achieved complete remission after the first treatment cycle. Although all patients included in this cohort were determined to be MCL-1 dependent, there was no association of complete remission with increasing MCL-1 dependence. The most frequently observed treatment-emergent non-hematologic adverse events of Grade 3 or higher were diarrhea, tumor lysis syndrome, hypocalcemia, sepsis and hypotension.1

Sumitomo Dainippon Pharma Oncology (SDP Oncology) will also be presenting details regarding the trial design of a Phase 1 study evaluating TP-3654, a PIM kinase inhibitor, in patients with intermediate-2 and high-risk primary or secondary myelofibrosis. In addition, SDP Oncology and its parent company, Sumitomo Dainippon Pharma Co. Ltd., will be presenting Phase 1 data evaluating alvocidib in combination with cytarabine and mitoxantrone in patients with relapsed/refractory AML or cytarabine and daunorubicin in patients with newly diagnosed AML. Finally, preclinical data evaluating how dubermatinib (TP-0903), an oral AXL kinase inhibitor, modulates CART19 will be presented.

"These findings presented at the ASH (Free ASH Whitepaper) Annual Meeting represent the first data evaluating the clinical activity of alvocidib in patients with newly diagnosed, high-risk, MCL-1-dependent AML," said Patricia S. Andrews, CEO and Global Head of Oncology, SDP Oncology. "The completion of this study marks a milestone for SDP Oncology as we continue to learn more about the optimal patient population that may benefit from alvocidib. The breadth of updates we presented at ASH (Free ASH Whitepaper) 2020 from across our pipeline demonstrate our commitment to advancing purposeful science by transforming new discoveries into meaningful therapeutic options for patients with cancer."

Below are the details for the SDP Oncology and Sumitomo Dainippon Pharma presentations:

Abstract Title

Details

Presenter

Zella 201: A Biomarker-Guided Phase II
Study of Alvocidib Followed by
Cytarabine and Mitoxantrone in MCL-1
Dependent Acute Myeloid Leukemia
(AML): Results of Newly Diagnosed High-
Risk Exploratory Arm

Abstract #1045

Saturday, December 5 at
7:00 a.m. PST

Virtual Poster Presentation

Joshua F. Zeidner, M.D.

University of North Carolina

A Phase 1 Study of TP-3654, an Orally-
Delivered PIM Kinase Inhibitor, in
Patients with Intermediate-2 or High-Risk
Primary or Secondary Myelofibrosis

Abstract #1251

Saturday, December 5 at
7:00 a.m. PST

Virtual Poster Presentation

Claudia Lebedinsky, M.D.

Sumitomo Dainippon
Pharma Oncology, Inc.

Axl-RTK Inhibition Modulates Monocyte
Immune Response to Enhance the Anti-
Tumor Effects of CD19 Redirected
Chimeric Antigen Receptor T Cells in
Preclinical Models

Abstract #1430

Saturday, December 5 at
7:00 a.m. PST

Virtual Poster Presentation

Reona Sakemura, M.D., Ph.D.

Mayo Clinic, Rochester, MN

Phase 1 Study of Alvocidib (DSP-2033) in
Combination with
Cytarabine/Mitoxantrone (ACM) or
Cytarabine/Daunorubicin (A+7+3) in
Japanese Patients (pts) with Acute
Myeloid Leukemia (AML)

Abstract #2831

Monday, December 7 at
7:00 a.m. PST

Virtual Poster Presentation

Yasuyoshi Morita, M.D.
Kindai University,
Higashiosaka, Osaka, Japan

For more information about SDP Oncology’s pipeline and clinical trials, please visit the company’s virtual booth at the ASH (Free ASH Whitepaper) Annual Meeting here.

About Alvocidib

Alvocidib is an investigational small molecule inhibitor of cyclin-dependent kinase 9 (CDK9) currently being evaluated in the ongoing Phase 2 Zella 202 study in patients with acute myeloid leukemia (AML) who have either relapsed from or are refractory to venetoclax in combination with azacitidine or decitabine (NCT03969420). Alvocidib is also being evaluated in Zella 102, a Phase 1b/2 study in patients with myelodysplastic syndromes (MDS) in combination with azacitidine or decitabine (NCT03593915) and in a Phase 1 study in patients with relapsed or refractory AML in combination with venetoclax (NCT03441555).

About CDK9 Inhibition and MCL-1

MCL-1 is a member of the apoptosis-regulating BCL-2 family of proteins.2 In normal function, it is essential for early embryonic development and for the survival of multiple cell lineages, including lymphocytes and hematopoietic stem cells.3 MCL-1 inhibits apoptosis and sustains the survival of leukemic blasts, which may lead to relapse or resistance to treatment.2,4 The expression of MCL-1 in leukemic blasts is regulated by cyclin-dependent kinase 9 (CDK9).5,6 Because of the short half-life of MCL-1 (2-4 hours), the effects of targeting upstream pathways are expected to reduce MCL-1 levels rapidly.5 Inhibition of CDK9 has been shown to block MCL-1 transcription, resulting in the rapid downregulation of MCL-1 protein, thus restoring the normal apoptotic regulation.2

About TP-3654

TP-3654 is an investigational second-generation selective PIM kinase inhibitor currently under evaluation in a Phase 1 study in patients with myelofibrosis (NCT04176198) and a Phase 1 study in patients with advanced solid tumors (NCT03715504).

About PIM Kinase

PIM kinases are major effectors of JAK/STAT proliferative signaling downstream of multiple growth factors and cytokines.7 PIM is overexpressed in cancers and it may enhance the ability of fibroblasts to differentiate into myofibroblasts.7

About Dubermatinib (TP-0903)

Dubermatinib is an investigational oral AXL receptor tyrosine kinase (RTK) inhibitor under evaluation in a Phase 1a/b study in patients with advanced solid tumors (NCT02729298) and an ongoing study in collaboration with the Leukemia & Lymphoma Society as part of the Beat AML Clinical Trial (NCT03013998). SDP Oncology is exploring parallel clinical development paths for dubermatinib in both solid and hematologic malignancies.

About AXL Kinase

AXL belongs to the TAM (Tyro3, AXL and Mer) family of receptor tyrosine kinases and is overexpressed in many human cancers.8 It plays a key role in tumor cell proliferation, survival, metastasis, cellular adhesion, and avoidance of the immune response. The overexpression of AXL is associated with a poor patient prognosis and drug resistance.9